CompletedPhase 2NCT00070018
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Thomas P. Miller, MD, MDUniversity of Arizona
- Intervention
- rituximab(biological)
- Enrollment
- 46 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2015
Study locations (30)
- Alaska Regional Hospital Cancer Center, Anchorage, Alaska, United States
- Providence Cancer Center, Anchorage, Alaska, United States
- Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
- Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States
- Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
- Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States
- Edward Hospital Cancer Center, Naperville, Illinois, United States
- Regional Cancer Center at Memorial Medical Center, Springfield, Illinois, United States
- Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States
- Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States
- Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States
- Cancer Center of Kansas-Independence, Independence, Kansas, United States
- Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States
- Southwest Medical Center, Liberal, Kansas, United States
- Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00070018 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic